Effects of CSL324 in the Lung After Segmental Challenge
A Phase 1b, Randomized, Double-blind, Placebo-controlled Study in Healthy Volunteers to Investigate the Effects of CSL324 in the Lung After Segmental Challenge With Endotoxin
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Trial Registration Coordinator
- Phone Number: 610-878-4000
- Email: clinicaltrials@cslbehring.com
Study Locations
-
-
-
Hannover, Germany, 30625
- Fraunhofer Institute for Toxicology and Experimental Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female volunteer.
- Between the ages of ≥ 18 and ≤ 65 years.
- Body mass index within the range of 18 to 32 kg/m2
- Female of nonchildbearing potential or of childbearing potential and willing to use a highly effective method of contraception (in addition to male partner condom with or without spermicide)
- Nonsmoker or an ex-smoker who has stopped smoking (including e-cigarettes or vaping devices) for > 1 year with a smoking history of < 10 pack-years.
Exclusion Criteria:
- Any clinically significant abnormalities in physical examination findings, electrocardiogram (ECG) readings, safety laboratory test results, or ANC < 2.0 × 109 cells/L.
- History of myeloproliferative or lymphoproliferative disease.
- Current or previous history of any immunosuppressive condition.
- Currently receiving any immunosuppressive or immunomodulatory therapy, or history of undergoing such therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CSL324
Intravenous (IV) dose of CSL324
|
Single intravenous (IV) dose of CSL324
Other Names:
|
|
Placebo Comparator: Placebo
IV dose of 0.9% saline
|
IV dose of 0.9% saline
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent reduction in mean absolute neutrophil cell counts in bronchoalveolar lavage fluid (BALF) between CSL324 and placebo
Time Frame: Obtained at 24 hours after the segmental lipopolysaccharide (LPS) challenge with endotoxin in the lung
|
Obtained at 24 hours after the segmental lipopolysaccharide (LPS) challenge with endotoxin in the lung
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent reduction in the mean change in biomarkers of neutrophil activation in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo
Time Frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
Biomarkers are (neutrophil elastase [NE], alpha [α] 1 antitrypsin [AAT) complex, and myeloperoxidase [MPO]) in BALF
|
Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
|
Percent reduction in the mean change in total protein in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo
Time Frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
|
|
Percent reduction in the mean change in concentrations of von Willebrand factor (vWF) in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo
Time Frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
|
|
Percent reduction in the mean change in concentrations of surfactant protein D (SP D) in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo
Time Frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
|
|
Percent reduction in the mean change in concentrations of sRAGE in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo
Time Frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
|
|
Percent reduction in the mean change in concentrations of G CSF in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo
Time Frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
|
|
Percent reduction in the mean change in concentrations of VEGF A in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo
Time Frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung
|
|
|
Serum concentration of CSL324
Time Frame: Up to 6 days after CSL324 administration
|
Up to 6 days after CSL324 administration
|
|
|
Number of subjects with antidrug antibodies (ADAs) to CSL324 in serum
Time Frame: Prior to and up to 6 days after CSL324 and placebo administration
|
Prior to and up to 6 days after CSL324 and placebo administration
|
|
|
Number and percentage of subjects with treatment-emergent adverse events (TEAEs) by treatment group
Time Frame: Up to 32 days after CSL324 and placebo administration
|
Up to 32 days after CSL324 and placebo administration
|
|
|
Maximum plasma concentration (Cmax)
Time Frame: Prior to and up to 6 days after CSL324 administration
|
Prior to and up to 6 days after CSL324 administration
|
|
|
Time to reach Cmax (Tmax)
Time Frame: Prior to and up to 6 days after CSL324 administration
|
Prior to and up to 6 days after CSL324 administration
|
|
|
Area under the plasma concentration-time curve from time 0 to 120 hours (AUC0-120h)
Time Frame: Time 0 to 120 hours after CSL324 administration
|
Time 0 to 120 hours after CSL324 administration
|
|
|
Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-last)
Time Frame: Time 0 and up to 6 days after CSL324 administration
|
Time 0 and up to 6 days after CSL324 administration
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Study Director, CSL Behring
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CSL324_1004
- 2022-002404-20 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Proposed research should seek to answer a previously unanswered important medical or scientific question.
Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.
If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.